Weichhart Thomas, Säemann Marcus D
Department of Internal Medicine III, Clinical Division of Nephrology and Dialysis, Medical University Vienna, Währinger Gürtel 18 - 20, A-1090 Vienna, Austria.
Trends Immunol. 2009 May;30(5):218-26. doi: 10.1016/j.it.2009.02.002. Epub 2009 Apr 8.
The mammalian target of rapamycin (mTOR) is an evolutionarily conserved serine-threonine kinase that is known to sense the environmental and cellular nutrition status to control cell growth. In immunity, mTOR is essential for both the proper activation and subsequent proliferation of effector T cells, yet also restrains the development of regulatory T cells. However, in monocytes/macrophages and peripheral myeloid dendritic cells, mTOR restricts proinflammatory and promotes anti-inflammatory responses, whereas, in plasmacytoid dendritic cells, mTOR fosters type I interferon production. These results place mTOR in a novel immunoregulatory context that highlights the potential of mTOR inhibitors as both immunosuppressant and anti-cancer agents.
雷帕霉素的哺乳动物靶点(mTOR)是一种在进化上保守的丝氨酸-苏氨酸激酶,已知其可感知环境和细胞营养状态以控制细胞生长。在免疫方面,mTOR对于效应T细胞的正常激活和随后的增殖至关重要,但同时也会抑制调节性T细胞的发育。然而,在单核细胞/巨噬细胞和外周髓样树突状细胞中,mTOR会限制促炎反应并促进抗炎反应,而在浆细胞样树突状细胞中,mTOR则会促进I型干扰素的产生。这些结果将mTOR置于一种新的免疫调节背景下,凸显了mTOR抑制剂作为免疫抑制剂和抗癌药物的潜力。